相关实验视频

Updated: Jun 22, 2025

Quantitative Analysis of Chromatin Proteomes in Disease

Quantitative Analysis of Chromatin Proteomes in Disease

Published on: December 28, 2012

使用基于蛋白质学的共识聚类来识别乙胆受体-抗体肌痛性骨髓炎的疾病表型

Christopher Nelke¹, Christina B Schroeter¹, Sumanta Barman¹

¹Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany.

|July 3, 2024

概括

这项研究使用血清蛋白质学识别了四种不同的肌痛性肌痛症患者表型. 一个表型 (PS3) 显示高严重性和补充激活,表明补充抑制疗法对这些严重肌痛症患者有益.

科学领域:

免疫学免疫学免疫学
蛋白质组学是指蛋白质组学.
自免疫性疾病自免疫性疾病

背景情况:

骨髓灰质炎 (MG) 呈现出临床异质性,使患者分层和治疗决策复杂化.
需要新的策略来根据生物表型对MG患者进行分类,以改善结果.

研究的目的:

用血清蛋白质学将抗乙胆受体-Ab-阳性MG患者分为不同的生物概况.
确定可能从特定治疗干预中受益的患者子组.

主要方法:

使用共识聚类对140名MG患者的血清蛋白质组分析.
免疫基因组测序B细胞谱在一个小组的患者.
在体外补充激活试验中,使用初级人类肌肉细胞进行了测试.

主要成果:

根据血清蛋白质组模式确定了四种不同的患者表型.
PS3表型表现出高度的疾病严重性和显著的补充激活.
PS3患者表现出过膨胀的抗体克隆,并且更有可能从补充抑制疗法中受益.
这些发现在一个由18名患者组成的前性队列中得到了验证.

结论:

基于蛋白质组学的聚类提供了一种将患者分配到生物签名的方法.
这种分层策略可以识别可能受益于补充抑制的MG患者.
该研究为改善临床实践中的患者选择和治疗提供了一个框架.

关键词:

补充补充补充补充补充抑制是补充的抑制.达成共识的集群化是共识的集群化.骨髓灰质炎 (Myasthenia gravis) 是一个严重的疾病.蛋白质组学是指蛋白质组学.

更多相关视频

Quantitative Proteomics Workflow using Multiple Reaction Monitoring Based Detection of Proteins from Human Brain Tissue

Quantitative Proteomics Workflow using Multiple Reaction Monitoring Based Detection of Proteins from Human Brain Tissue

Published on: August 28, 2021

Consensus Brain-derived Protein, Extraction Protocol for the Study of Human and Murine Brain Proteome Using Both 2D-DIGE and Mini 2DE Immunoblotting

Consensus Brain-derived Protein, Extraction Protocol for the Study of Human and Murine Brain Proteome Using Both 2D-DIGE and Mini 2DE Immunoblotting

Published on: April 10, 2014

相关概念视频

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...